Αποτελέσματα Αναζήτησης
Κυριότερες Ειδήσεις
7 Νοε 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to...
- Management of patients with advanced-stage HER2-positive breast cancer ...
Amplification and/or overexpression of ERBB2, the gene...
- HER2-positive breast cancer and tyrosine kinase inhibitors ... - Nature
Human epidermal growth factor receptor 2 (HER2) positive...
- Management of patients with advanced-stage HER2-positive breast cancer ...
3 Μαΐ 2024 · Targeted Therapy Improves Survival for Metastatic “HER2-Low” Breast Cancer. Enhertu expected to become new standard for treating metastatic breast cancer with low HER2 protein levels.
8 Ιαν 2024 · Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical...
1 ημέρα πριν · Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...
19 Οκτ 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
20 Μαΐ 2021 · Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last...
10 Οκτ 2024 · On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone ...
